{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:49:57Z","timestamp":1785329397392,"version":"3.55.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2000,9,1]],"date-time":"2000-09-01T00:00:00Z","timestamp":967766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2000,9]]},"DOI":"10.1006\/gyno.2000.5921","type":"journal-article","created":{"date-parts":[[2002,9,17]],"date-time":"2002-09-17T18:50:18Z","timestamp":1032288618000},"page":"369-372","source":"Crossref","is-referenced-by-count":122,"title":["Phase 2 Trial of Liposomal Doxorubicin (40 mg\/m2) in Platinum\/Paclitaxel-Refractory Ovarian and Fallopian Tube Cancers and Primary Carcinoma of the Peritoneum"],"prefix":"10.1006","volume":"78","author":[{"given":"Maurie","family":"Markman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertrude","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kulp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Belinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1006\/gyno.2000.5921_RF1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1006\/gyno.2000.5921_RF2","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.1991.9.9.1668","article-title":"Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis","volume":"9","author":"Ovarian Cancer Meta","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5921_RF3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/JCO.1995.13.3.726","article-title":"Impact of doxorubicin on survival in advanced ovarian cancer","volume":"13","author":"A'Hern","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5921_RF4","first-page":"954","article-title":"Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma","volume":"80","author":"Fanning","year":"1992","journal-title":"Obstet Gynecol"},{"key":"10.1006\/gyno.2000.5921_RF5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1046\/j.1525-1438.1996.06040286.x","article-title":"Twelve-year follow-up of a randomized trial comparing cisplatin and cyclophosphamide with cisplatin, doxorubicin and cyclophosphamide in patients with advanced epithelial ovarian cancer","volume":"6","author":"Gadducci","year":"1996","journal-title":"Int J Gynecol Cancer"},{"key":"10.1006\/gyno.2000.5921_RF6","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1056\/NEJM199311183292108","article-title":"Cancer of the ovary","volume":"329","author":"Cannistra","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1006\/gyno.2000.5921_RF7","doi-asserted-by":"crossref","unstructured":"Singal, P, K, Iliskovic, N, Doxorubicin-induced cardiomyopathy, N Engl J Med, 339: 900, \u2013 905","DOI":"10.1056\/NEJM199809243391307"},{"key":"10.1006\/gyno.2000.5921_RF8","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.1995.13.7.1777","article-title":"Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies","volume":"13","author":"Uziely","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5921_RF9","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/jnci\/87.20.1556","article-title":"Lack of vesicant injury following extravasation of liposomal doxorubicin","volume":"87","author":"Madhavan","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1006\/gyno.2000.5921_RF10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5921_RF11","first-page":"349a","article-title":"Doxil (Doxorubicin HCL liposome injection) in the treatment of patients with refractory advanced epithelial ovarian carcinoma\u2014results of an interim analysis","volume":"17","author":"Gordon","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2000.5921_RF12","first-page":"360a","article-title":"Interim analysis of a non-comparative, multicenter study of Doxil\/Caelyx in the treatment of patients with refractory ovarian cancer","volume":"18","author":"Rose","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2000.5921_RF13","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","article-title":"Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study","volume":"10","author":"Markman","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5921_RF14","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.1995.13.12.2961","article-title":"Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study","volume":"13","author":"Francis","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5921_RF15","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1006\/gyno.1998.5065","article-title":"Phase 2 trial of single agent ifosfamide\/mesna in patients with platinum\/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent","volume":"70","author":"Markman","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2000.5921_RF16","first-page":"371a","article-title":"A retrospective analysis of the clinical utility of doxil in recurrent ovarian cancer (ROC)","volume":"18","author":"Campos","year":"1999","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825800959213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825800959213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T03:20:25Z","timestamp":1576466425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825800959213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,9]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,9]]}},"alternative-id":["S0090825800959213"],"URL":"https:\/\/doi.org\/10.1006\/gyno.2000.5921","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2000,9]]}}}